Nuformix (LON:NFX) Stock Price Down 12.7% – Should You Sell?

Shares of Nuformix plc (LON:NFX) were down 12.7% during trading on Tuesday . The company traded as low as GBX 0.06 ($0.00) and last traded at GBX 0.06 ($0.00). Approximately 16,142,512 shares were traded during trading, a decline of 74% from the average daily volume of 62,608,598 shares. The stock had previously closed at GBX 0.06 ($0.00).

Nuformix Stock Performance

The stock has a market cap of £450,620.50, a price-to-earnings ratio of -1.63 and a beta of 1.22. The firm’s 50-day moving average is GBX 0.05 and its two-hundred day moving average is GBX 0.10. The company has a current ratio of 1.12, a quick ratio of 3.35 and a debt-to-equity ratio of 1.17.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.